NHS National Framework for Transition Products (Nintedanib and Dalbavancin)
A Contract Award Notice
by NHS ENGLAND
- Source
- Find a Tender
- Type
- Framework ()
- Duration
- not specified
- Value
- £15M
- Sector
- MISCELLANEOUS
- Published
- 25 Feb 2026
- Delivery
- not specified
- Deadline
- n/a
Related Terms
Location
Geochart for 1 buyers and 7 suppliers
1 buyer
- NHS England London
7 suppliers
- Celix Pharma Watford
- Accord Devon
- Baxter Healthcare Reading
- DR Reddys Laboratories Cambridge
- Glenmark Pharmaceuticals Europe Watford
- Wockhardt Wrexham
- Zentiva Pharma Guildford
Description
Project title: NHS National Framework for Transition Products (Nintedanib and Dalbavancin) commencing 1st May 2026 Offer reference number: CM/TNS/25/5736 Period of framework agreement: Dates detailed below, with an option or options to extend (at the discretion of the Authority) up to a maximum of 24 months. CM/TNS/25/5736 Nintedanib and Dalbavancin Lot 1 DLN/DNW: 01/05/2026 to 30/09/2027 (17 months) Lot 2 DLS/DNE: 01/05/2026 to 31/05/2027 (13 months) Lot 3 DCE/DSW: 01/05/2026 to 31/01/2027 (9 months) Published By: Medicines Procurement and Supply Chain - NHS Medicines Value & Access, NHS England
Award Detail
| 1 | Celix Pharma (Watford)
|
| 2 | Accord (Devon)
|
| 3 | Baxter Healthcare (Reading)
|
| 4 | DR Reddys Laboratories (Cambridge)
|
| 5 | Glenmark Pharmaceuticals Europe (Watford)
|
| 6 | Wockhardt (Wrexham)
|
| 7 | Zentiva Pharma (Guildford)
|
CPV Codes
- None found
Indicators
Other Information
** PREVIEW NOTICE, please check Find a Tender for full details. **
Reference
- ocds-h6vhtk-05d361
- FTS 016881-2026